Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BIORESTORATIVE THERAPIES, INC. reported revenue of $0M, down 10.3% year over year. Operating margin was -4350.1% and net margin -3959.4%, on a free-cash-flow margin of -3031.7% with capital expenditure at 32.3% of revenue. Every figure is computed directly from BRTX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -4350.1% | -3959.4% |
| FY2024 | $0M | -2881.6% | -2239.2% |
| FY2023 | $0M | -10439.5% | -7145.2% |
| FY2022 | $0M | -15838.1% | -11037.0% |
| FY2021 | $0M | -57191.0% | -96311.5% |
How does BRTX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AACG · ABSI · ACCS · ACHC · ACM · ADUS
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.